{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:04:01Z","timestamp":1785542641481,"version":"3.56.0"},"reference-count":71,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The field\u00a0of malignant hematology has experienced extraordinary advancements with survival rates doubling for many disorders. As a result, many life-threatening conditions have since evolved into chronic medical ailments. Paralleling these advancements have been increasing rates of complex hematologic pain syndromes, present in up to 60% of patients with malignancy who are receiving active treatment and up to 33% of patients during survivorship. Opioids remain the practice cornerstone to managing malignancy-associated pain. Prevention and management of opioid-related complications have received significant national attention over the past decade, and emerging data suggest that patients with cancer are at equal if not higher risk of opioid-related complications when compared with patients without malignancy. Numerous tools and procedural practice guides are available to help facilitate safe prescribing. The recent development of cancer-specific resources directing algorithmic use of validated pain screening tools, prescription drug monitoring programs, urine drug screens, opioid use disorder risk screening instruments, and controlled substance agreements have further strengthened the framework for safe prescribing. This article, which integrates federal and organizational guidelines with known risk factors for cancer patients, offers a case-based discussion for reviewing safe opioid prescribing practices in the hematology setting.<\/jats:p>","DOI":"10.1182\/blood.2019003116","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T13:35:52Z","timestamp":1588253752000},"page":"2354-2364","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["How I treat pain in hematologic malignancies safely with opioid therapy"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3963-2350","authenticated-orcid":false,"given":"Holly L.","family":"Geyer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halena","family":"Gazelka","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Mayo Clinic, Rochester, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"first","affiliation":[{"name":"Department of Hematology, University of Texas Health San Antonio Cancer Center, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020062511295154700_B1","unstructured":"Centers for Disease Control and Prevention . CDC\u2019s Response to the Opioid Overdose Epidemic.2019. https:\/\/www.cdc.gov\/opioids\/index.html. Accessed October 2019."},{"issue":"1","key":"2020062511295154700_B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"2020062511295154700_B3","volume-title":"Cancer Facts & Figures 2019","author":"American Cancer Society","year":"2019"},{"issue":"36","key":"2020062511295154700_B4","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.15585\/mmwr.mm6736a2","article-title":"Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016","volume":"67","author":"Dahlhamer","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"2020062511295154700_B5","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","article-title":"Prevalence of pain in patients with cancer: a systematic review of the past 40 years","volume":"18","author":"van den Beuken-van Everdingen","year":"2007","journal-title":"Ann Oncol"},{"issue":"8","key":"2020062511295154700_B6","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/annonc\/mdp001","article-title":"Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes","volume":"20","author":"Breivik","year":"2009","journal-title":"Ann Oncol"},{"key":"2020062511295154700_B7","first-page":"53","volume-title":"Cancer Pain: Assessment and Management","author":"Bruera","year":"2010"},{"issue":"6","key":"2020062511295154700_B8","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1634\/theoncologist.2013-0001","article-title":"Predictors of long-term opioid treatment among patients who receive chemoradiation for head and neck cancer","volume":"18","author":"Kwon","year":"2013","journal-title":"Oncologist"},{"issue":"36","key":"2020062511295154700_B9","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2017.74.1363","article-title":"New persistent opioid use among patients with cancer after curative-intent surgery","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020062511295154700_B10","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00520-014-2167-6","article-title":"Screening for substance abuse risk in cancer patients using the Opioid Risk Tool and urine drug screen","volume":"22","author":"Barclay","year":"2014","journal-title":"Support Care Cancer"},{"issue":"6","key":"2020062511295154700_B11","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00520-017-3575-1","article-title":"Urine drug screen findings among ambulatory oncology patients in a supportive care clinic","volume":"25","author":"Rauenzahn","year":"2017","journal-title":"Support Care Cancer"},{"issue":"6","key":"2020062511295154700_B12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1634\/theoncologist.2015-0012","article-title":"Frequency, predictors, and medical record documentation of chemical coping among advanced cancer patients","volume":"20","author":"Kwon","year":"2015","journal-title":"Oncologist"},{"issue":"3","key":"2020062511295154700_B13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/jpm.2012.0263","article-title":"Screening for substance abuse and diversion in Virginia hospices","volume":"16","author":"Blackhall","year":"2013","journal-title":"J Palliat Med"},{"issue":"36","key":"2020062511295154700_B14","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1200\/JCO.2014.56.0383","article-title":"Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer","volume":"32","author":"Greco","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020062511295154700_B15","first-page":"89","article-title":"Why patients are afraid of opioid analgesics: a study on opioid perception in patients with chronic pain","volume":"128","author":"Graczyk","year":"2018","journal-title":"Pol Arch Intern Med"},{"key":"2020062511295154700_B16","unstructured":"Cancer Action Network, American Cancer Society . New data: Some measures meant to address opioid abuse are having adverse impact on access to legitimate pain care for patients. https:\/\/www.fightcancer.org\/releases\/new-data-some-measures-meant-address-opioid-abuse-are-having-adverse-impact-access. Accessed October 2019."},{"issue":"21","key":"2020062511295154700_B17","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.4067.4067","article-title":"Myeloproliferative (MPN) symptom burden response thresholds: Assessment of MPN-SAF TSS quartiles as potential markers of symptom response [abstract]","volume":"122","author":"Emanuel","year":"2013","journal-title":"Blood"},{"key":"2020062511295154700_B18","first-page":"209","volume-title":"International Association for the Study of Pain (IASP) Task Force on Taxonomy, Classification of Chronic Pain","author":"Merskey","year":"1994","edition":"2nd ed"},{"issue":"2","key":"2020062511295154700_B19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jpain.2004.11.002","article-title":"Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale","volume":"6","author":"Jensen","year":"2005","journal-title":"J Pain"},{"issue":"4","key":"2020062511295154700_B20","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0959-4388(94)90053-1","article-title":"The pathophysiology of chronic pain--increased sensitivity to low threshold A beta-fibre inputs","volume":"4","author":"Woolf","year":"1994","journal-title":"Curr Opin Neurobiol"},{"key":"2020062511295154700_B21","unstructured":"World Health Organization . WHO\u2019s Cancer Pain Ladder for Adults.2019. https:\/\/www.who.int\/cancer\/palliative\/painladder\/en\/. Accessed October 2019."},{"key":"2020062511295154700_B22","unstructured":"World Health Organization . Cancer Pain Relief with a Guide to Opioid Availability. (2nd ed). Geneva, Switzerland: World Health Organization; 1996."},{"issue":"1","key":"2020062511295154700_B23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0304-3959(95)00017-M","article-title":"Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study","volume":"63","author":"Zech","year":"1995","journal-title":"Pain"},{"issue":"2","key":"2020062511295154700_B24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpainsymman.2014.05.021","article-title":"Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial","volume":"49","author":"Riley","year":"2015","journal-title":"J Pain Symptom Manage"},{"key":"2020062511295154700_B25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.14694\/EDBK_180469","article-title":"Pain and opioids in cancer care: Benefits, risks, and alternatives","volume":"37","author":"Bennett","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"2020062511295154700_B26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/pon.627","article-title":"Patient barriers to optimal cancer pain control","volume":"12","author":"Potter","year":"2003","journal-title":"Psychooncology"},{"issue":"1","key":"2020062511295154700_B27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00520-015-2786-6","article-title":"Unplanned oncology admissions within 14 days of non-surgical discharge: a retrospective study","volume":"24","author":"Gibson","year":"2016","journal-title":"Support Care Cancer"},{"key":"2020062511295154700_B28","author":"Chou","year":"2009"},{"key":"2020062511295154700_B29","unstructured":"Chou R , DeyoR, DevineB, et al The effectiveness and risks of long-term opioid treatment of chronic pain. Evidence Report\/Technology Assessment No. 218. Agency for Healthcare Research and Quality Publication No. 14-E005-EF. https:\/\/effectivehealthcare.ahrq.gov\/sites\/default\/files\/pdf\/chronic-pain-opioid-treatment_research.pdf. Accessed October 2019."},{"issue":"4","key":"2020062511295154700_B30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7326\/M14-2559","article-title":"The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop","volume":"162","author":"Chou","year":"2015","journal-title":"Ann Intern Med"},{"issue":"6","key":"2020062511295154700_B31","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1213\/ANE.0000000000000672","article-title":"Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations","volume":"120","author":"Correa","year":"2015","journal-title":"Anesth Analg"},{"issue":"2","key":"2020062511295154700_B32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.36076\/ppj.2011\/14\/145","article-title":"A comprehensive review of opioid-induced hyperalgesia","volume":"14","author":"Lee","year":"2011","journal-title":"Pain Physician"},{"key":"2020062511295154700_B33","unstructured":"World Health Organization . Information Sheet on Opioid Overdose.https:\/\/www.who.int\/substance_abuse\/information-sheet\/en\/. Accessed October 2019."},{"issue":"5","key":"2020062511295154700_B34","doi-asserted-by":"crossref","first-page":"e193365","DOI":"10.1001\/jamanetworkopen.2019.3365","article-title":"Strategies to identify patient risks of prescription opioid addiction when initiating opioids for pain: A systematic review","volume":"2","author":"Klimas","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"9","key":"2020062511295154700_B35","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/add.13795","article-title":"Hospitalizations, costs and outcomes associated with heroin and prescription opioid overdoses in the United States 2001-12","volume":"112","author":"Hsu","year":"2017","journal-title":"Addiction"},{"issue":"1","key":"2020062511295154700_B36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00726-011-1163-0","article-title":"Role of the mu-opioid receptor in opioid modulation of immune function","volume":"45","author":"Ninkovi\u0107","year":"2013","journal-title":"Amino Acids"},{"issue":"37","key":"2020062511295154700_B37","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.2174\/138161212803582496","article-title":"Non-analgesic effects of opioids: mechanisms and potential clinical relevance of opioid-induced immunodepression","volume":"18","author":"Sacerdote","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"3","key":"2020062511295154700_B38","doi-asserted-by":"crossref","first-page":"e91577","DOI":"10.1371\/journal.pone.0091577","article-title":"The mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and epithelial mesenchymal transition (EMT) in human lung cancer","volume":"9","author":"Lennon","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"2020062511295154700_B39","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1213\/ANE.0b013e31820568af","article-title":"The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation","volume":"112","author":"Mathew","year":"2011","journal-title":"Anesth Analg"},{"issue":"6","key":"2020062511295154700_B40","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1213\/ANE.0b013e318232b35a","article-title":"Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer","volume":"113","author":"Fujioka","year":"2011","journal-title":"Anesth Analg"},{"issue":"suppl 1","key":"2020062511295154700_B41","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/bja\/aeu090","article-title":"Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer","volume":"113","author":"Nguyen","year":"2014","journal-title":"Br J Anaesth"},{"issue":"suppl 4","key":"2020062511295154700_B67","doi-asserted-by":"crossref","first-page":"iv166","DOI":"10.1093\/annonc\/mdy152","article-title":"Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines","volume":"29","author":"Fallon","year":"2018","journal-title":"Ann Oncol"},{"issue":"27","key":"2020062511295154700_B54","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.2016.68.5206","article-title":"Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Paice","year":"2016","journal-title":"J Clin Oncol"},{"key":"2020062511295154700_B68","unstructured":"National Conference of State Legislatures . Prescribing Policies: States Confront Opioid Overdose Epidemic. https:\/\/www.ncsl.org\/research\/health\/prescribing-policies-states-confront-opioid-overdose-epidemic.aspx. Accessed October 2019."},{"key":"2020062511295154700_B65","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013","edition":"ed 5"},{"issue":"6","key":"2020062511295154700_B55","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11606-009-0981-1","article-title":"Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference","volume":"24","author":"Krebs","year":"2009","journal-title":"J Gen Intern Med"},{"issue":"9","key":"2020062511295154700_B56","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"3","key":"2020062511295154700_B57","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MLR.0b013e318160d093","article-title":"Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population","volume":"46","author":"L\u00f6we","year":"2008","journal-title":"Med Care"},{"key":"2020062511295154700_B69","unstructured":"National Institute on Drug Abuse . Sample Patient Agreement Forms.https:\/\/www.drugabuse.gov\/sites\/default\/files\/files\/SamplePatientAgreementForms.pdf. Accessed October 2019."},{"key":"2020062511295154700_B70","unstructured":"U.S. Department of Health and Human Services . Safe Opioid Prescribing. (https:\/\/www.hhs.gov\/opioids\/prevention\/safe-opioid-prescribing\/index.html). Accessed October 2019."},{"key":"2020062511295154700_B71","unstructured":"Substance Abuse and Mental Health Services Administration . SAMHSA\u2019s National Helpline.https:\/\/www.samhsa.gov\/find-help\/national-helpline. Accessed October 2019."},{"key":"2020062511295154700_B72","unstructured":"Substance Abuse and Mental Health Services Administration . Behavioral Health Treatment Services Locator.https:\/\/findtreatment.samhsa.gov. Accessed October 2019."},{"issue":"5","key":"2020062511295154700_B42","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1213\/ANE.0000000000002496","article-title":"Risk factors for opioid-use disorder and overdose","volume":"125","author":"Webster","year":"2017","journal-title":"Anesth Analg"},{"issue":"3","key":"2020062511295154700_B43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5055\/jom.2016.0333","article-title":"Risk factors for opioid misuse in adolescents and young adults with focus on oncology setting","volume":"12","author":"Peck","year":"2016","journal-title":"J Opioid Manag"},{"issue":"3","key":"2020062511295154700_B44","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jpainsymman.2012.02.023","article-title":"Frequency and predictors of patient deviation from prescribed opioids and barriers to opioid pain management in patients with advanced cancer","volume":"45","author":"Nguyen","year":"2013","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"2020062511295154700_B45","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/pme.12100","article-title":"Risk stratification of opioid misuse among patients with cancer pain using the SOAPP-SF","volume":"14","author":"Koyyalagunta","year":"2013","journal-title":"Pain Med"},{"issue":"6","key":"2020062511295154700_B46","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1526-4637.2005.00072.x","article-title":"Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool","volume":"6","author":"Webster","year":"2005","journal-title":"Pain Med"},{"issue":"2","key":"2020062511295154700_B47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5055\/jom.2015.0266","article-title":"Validation of a new risk assessment tool: the Brief Risk Questionnaire","volume":"11","author":"Jones","year":"2015","journal-title":"J Opioid Manag"},{"issue":"5","key":"2020062511295154700_B48","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jpainsymman.2003.10.009","article-title":"Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients","volume":"27","author":"Adams","year":"2004","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"2020062511295154700_B49","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/10550887.2016.1107264","article-title":"Risk factors for opioid overdose and awareness of overdose risk among veterans prescribed chronic opioids for addiction or pain","volume":"35","author":"Wilder","year":"2016","journal-title":"J Addict Dis"},{"issue":"6","key":"2020062511295154700_B50","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/ADM.0000000000000354","article-title":"Concurrent use of opioids and benzodiazepines: Evaluation of prescription drug monitoring by a United States Laboratory","volume":"11","author":"McClure","year":"2017","journal-title":"J Addict Med"},{"issue":"10","key":"2020062511295154700_B51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.15585\/mmwr.mm6610a1","article-title":"Characteristics of initial prescription episodes and likelihood of long-term opioid use - United States, 2006-2015","volume":"66","author":"Shah","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"2020062511295154700_B52","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpain.2008.10.008","article-title":"Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain","volume":"10","author":"Chou","year":"2009","journal-title":"J Pain"},{"key":"2020062511295154700_B53","unstructured":"U.S. Department of Veterans Affairs . VA\/DoD Clinical Practice Guidelines: management of opioid therapy (OT) for chronic pain (2017). http:\/\/www.healthquality.va.gov\/guidelines\/Pain\/cot. Accessed October 2019."},{"issue":"1","key":"2020062511295154700_B58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4065\/83.1.66","article-title":"Urine drug screening: practical guide for clinicians","volume":"83","author":"Moeller","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2020062511295154700_B59","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/ADM.0000000000000493","article-title":"Opioid and cannabis co-use among adults with chronic pain: Relations to substance misuse, mental health, and pain experience","volume":"13","author":"Rogers","year":"2019","journal-title":"J Addict Med"},{"key":"2020062511295154700_B60","unstructured":"American Society of Addiction Medicine . Definition of Addiction.2011. https:\/\/www.asam.org\/resources\/definition-of-addiction. Accessed October 2019."},{"issue":"4","key":"2020062511295154700_B62","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.j.pain.0000460357.01998.f1","article-title":"Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis","volume":"156","author":"Vowles","year":"2015","journal-title":"Pain"},{"key":"2020062511295154700_B63","unstructured":"Alabdulhadi O . Prospective cohort study to assess the risk of substance abuse in cancer patients being treated with opioid analgesics for severe cancer pain. International Association for the Study of Pain 14th World Congress on Pain; 26-31 August 2012; Milan, Italy. Abstract PT389."},{"issue":"7","key":"2020062511295154700_B64","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1089\/jpm.2008.0037","article-title":"Alcoholism screening in patients with advanced cancer: impact on symptom burden and opioid use","volume":"11","author":"Parsons","year":"2008","journal-title":"J Palliat Med"},{"issue":"12","key":"2020062511295154700_B66","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch Gen Psychiatry"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/26\/2354\/1745407\/bloodbld2019003116c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/26\/2354\/1745407\/bloodbld2019003116c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T17:40:52Z","timestamp":1666460452000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/26\/2354\/454705\/How-I-treat-pain-in-hematologic-malignancies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":71,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2020,6,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019003116","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,25]]}}}